Cargando…
New options for the anemia of chronic kidney disease
Anemia is a common complication of chronic kidney disease. Use of erythropoiesis-stimulating agents (ESA) has been a mainstay of treatment since 1990. A series of large trials demonstrated that ESAs have serious safety problems, including increasing cardiovascular and thrombotic events, and death. A...
Autores principales: | Coyne, Daniel W., Goldsmith, David, Macdougall, Iain C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341017/ https://www.ncbi.nlm.nih.gov/pubmed/30675430 http://dx.doi.org/10.1016/j.kisu.2017.09.002 |
Ejemplares similares
-
Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease
por: Larson, Derek S., et al.
Publicado: (2013) -
Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions
por: Macdougall, Iain C
Publicado: (2017) -
Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data
por: Dmitrieva, Olga, et al.
Publicado: (2013) -
The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia
por: Kassianides, Xenophon, et al.
Publicado: (2021) -
Special issue: iron therapy in patients with chronic kidney disease
por: Macdougall, Iain C
Publicado: (2017)